Mostrar el registro sencillo del ítem

Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns

dc.creatorApiquián, Rogelio
dc.creatorFresán, Ana
dc.creatorDe la Fuente-Sandoval, Camilo
dc.creatorUlloa, Rosa-Elena
dc.creatorNicolini, Humberto
dc.date.accessioned2017-06-29T04:32:03Z
dc.date.available2017-06-29T04:32:03Z
dc.date.issued2004es_ES
dc.identifier417es_ES
dc.identifier.issn1471-244Xes_ES
dc.identifier.urihttp://www.biomedcentral.com/1471-244X/4/12es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/5106
dc.identifier.urihttps://doi.org/10.1186/1471-244X-4-12es_ES
dc.language.isoenges_ES
dc.relation4 (12) 1-7 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.titleSurvey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patternses_ES
dc.typearticlees_ES
dc.contributor.affiliationClinical Research Division, National Institute of Psychiatry Ramón de la Fuente, Mexico City, Mexicoes_ES
dc.contributor.emailrogelioapiquian@yahoo.com.mxes_ES
dc.relation.jnabreviadoBMC PSYCHIATRYes_ES
dc.relation.journalBMC psychiatryes_ES
dc.identifier.placeLondones_ES
dc.date.published2004es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.doi10.1186/1471-244X-4-12es_ES
dc.description.abstractotrodiomaBackground Since the introduction of antipsychotics, especially the so called atypicals, the treatment of schizophrenia has shown important improvements. At the present time, it is preferred to label clozapine and other antipsychotics sharing similar profiles as second-generation antipsychotics (SGAs). These medications have been proposed by some experts as a first line treatment for schizophrenia. It is critical to have reliable data about antipsychotic prescription in Mexico and to create management guidelines based on expert meetings and not only on studies carried out by the pharmaceutical industry. Only this approach will help to make the right decisions for the treatment of schizophrenia. Methods A translated version of Rabinowitz's survey was used to evaluate antipsychotic prescription preferences and patterns in Mexican psychiatrists. The survey questionnaire was sent by mail to 200 psychiatrists from public institutions and private practice in Mexico City and Guadalajara, Mexico. Results Recommendations for antipsychotics daily doses at different stages of the treatment of schizophrenia varied widely. Haloperidol was considered as the first choice for the treatment of positive symptoms. On the contrary, risperidone was the first option for negative symptoms. For a patient with a high susceptibility for developing extrapyramidal symptoms (EPS), risperidone was the first choice. It was also considered that SGAs had advantages over typical antipsychotics in the management of negative symptoms, cognitive impairment and fewer EPS. Besides, there was a clear tendency for prescribing typical antipsychotics at higher doses than recommended and inadequate doses for the atypical ones. Conclusions Some of the obstacles for the prescription of SGAs include their high cost, deficient knowledge about their indications and dosage, the perception of their being less efficient for the treatment of positive symptoms and the resistance of some Mexican physicians to change their prescription pattern. It is necessary to reach a consensus, in order to establish and standardize the treatment of schizophrenia, based on the information reported in clinical trials and prevailing economic conditions in Mexicoes_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem